The FDA accepted Moderna's revised influenza vaccine filing after initially refusing to review the original submission. The acceptance puts Moderna's mRNA flu vaccine on track for potential approval in time for the 2026–27 flu season.
Longevity News
The FDA has accepted Moderna’s revised influenza vaccine filing days after controversially refusing to review the ori...
Source: FierceBiotech - All • Published: 20 Feb 2026, 04:51
Continue exploring
Related longevity signals
Nature - MainModerna cancer vaccine stops melanoma returning: what’s next for personalized treatments?Personalized mRNA cancer vaccines are the focus of a news article explaining trial developments and implications for tailored melanoma treatment strategies.Frontiers - HealthAdvances in Rapid ADAMTS13 Testing for Thrombotic Thrombocytopenic Purpura: A Systematic Review of Diagnostic Assays and the Role of Clinical Probability ToolsRapid-testing and clinical-score advances for diagnosing acute TTP are described, previewing a review of assays, prediction tools, and diagnostic pathways.Frontiers - HealthTelitacicept in myasthenia gravis: a systematic review of clinical outcomes, steroid-sparing effects, and safetyA systematic review synthesizes clinical evidence on a B-cell–targeting biologic for myasthenia gravis, focusing on outcomes, steroid reduction, and safety.Frontiers - HealthMachine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes in Breast Cancer Histopathology: A Systematic Review and Evidence-Gap Analysis of Translational ReadinessAssessments of tumor-infiltrating lymphocytes in breast cancer using machine learning are reviewed and mapped for translational readiness and methodological gaps.